Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLC

May 25th 2023

The combination of sitravatinib and nivolumab did not meet the primary end point of overall survival compared with docetaxel as second- or third-line treatment for patients with advanced nonsquamous non–small cell lung cancer who progressed on prior chemotherapy and immune checkpoint inhibitor therapy.

Clinical Updates for the Management of Lung Cancer Brain Metastases

May 25th 2023

As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.

Dr Goldberg on Investigational Agents in EGFR-mutant NSCLC

May 24th 2023

Sarah Goldberg, MD, MPH, discusses ongoing investigations with antibody-drug conjugates and bispecific antibodies in patients with non–small cell lung cancer harboring EGFR mutations.

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

May 23rd 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Combination Chemotherapy and Immunotherapy for Advanced NSCLC

May 23rd 2023

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

The Evolution of Chemoimmunotherapy in Advanced NSCLC

May 23rd 2023

Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Dr Cummings on Adjuvant Osimertinib in EGFR-Mutant NSCLC

May 19th 2023

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

May 19th 2023

John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.

Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer

May 19th 2023

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing

May 19th 2023

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

May 19th 2023

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

May 18th 2023

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

First-line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefit in PD-L1+ NSCLC

May 17th 2023

Eftilagimod alpha plus pembrolizumab provided an overall survival benefit over what has been reported with historical controls when given as first-line treatment in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of at least 1%.

Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC

May 17th 2023

The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

May 16th 2023

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

May 16th 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

May 16th 2023

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC

May 16th 2023

The use of docetaxel and ramucirumab yielded antitumor activity and showcased a manageable safety profile in patients with non–small cell lung cancer who progressed on platinum-based chemotherapy and immune checkpoint inhibitors, according to data from the phase 2 SCORPION study.

Dr Khalil on the Future Investigations of Immunotherapy in NSCLC

May 15th 2023

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.